Wedmont Private Capital Has $313,000 Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Wedmont Private Capital lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 24.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,538 shares of the medical research company’s stock after selling 504 shares during the period. Wedmont Private Capital’s holdings in IQVIA were worth $313,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its holdings in shares of IQVIA by 1.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 140,039 shares of the medical research company’s stock valued at $29,610,000 after acquiring an additional 2,576 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of IQVIA by 5.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock worth $253,125,000 after buying an additional 60,827 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in shares of IQVIA during the 2nd quarter worth $435,000. Mercer Global Advisors Inc. ADV grew its stake in IQVIA by 21.1% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 13,043 shares of the medical research company’s stock valued at $2,746,000 after buying an additional 2,277 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. raised its holdings in IQVIA by 3.0% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 9,112 shares of the medical research company’s stock worth $1,927,000 after acquiring an additional 264 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 0.8 %

Shares of IQV opened at $197.71 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $35.89 billion, a PE ratio of 25.95, a PEG ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock has a 50 day simple moving average of $200.93 and a 200-day simple moving average of $221.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Robert W. Baird lowered their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Bank of America dropped their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Finally, Truist Financial decreased their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.